Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Revolution Medicines

6 shared events · Importance 3 · Last updated Aug 27, 2026

Importance
3
Shared Events
6
Actions
2
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
100
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Revolution Medicines: Revolution Medicines received FDA approval for its lead drug daraxonrasib (Rasonque), a first-in-class RAS inhibitor. The approval is expected to drive substantial revenue growth, with analysts projecting up to $11.5 billion in annual sales, and the company's stock has risen 166% this year.
Aug 26, 2026 · 92 articles
95
Tech
United States — Food and Drug Administration: Granted expedited approval of daraxonrasib more than six months ahead of its target date, reinforcing its accelerated-review posture for serious diseases.
Revolution Medicines: Secures first approval and commercial launch of daraxonrasib under the Rasonque brand at about $39,800 per month, validating its KRAS molecular glue platform and opening expansion into other cancers.
Aug 26, 2026 · 6 articles
87
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.
Revolution Medicines: Revolution Medicines developed daraxonrasib, the experimental drug that has shown significant promise in treating advanced pancreatic cancer, leading to increased attention and potential for market growth for the company.
May 29, 2026 · 74 articles
77
Regulatory
United States — Food and Drug Administration: The FDA is reviewing a rolling NDA for daraxonrasib under a priority voucher program, which could expedite U.S. approval.
Revolution Medicines: Revolution Medicines is the developer of daraxonrasib; the EMA phased review and FDA submission progress are key regulatory milestones that could lead to market approval and significant revenue.
Jul 07, 2026 · 7 articles
42
Tech
United States — Food and Drug Administration: The FDA granted Orphan Drug Designation for PRP in pancreatic cancer, which provides regulatory support and potential market exclusivity.
Revolution Medicines: Revolution Medicines' daraxonrasib is referenced as a comparator with strong Phase 3 results. The comparison highlights the competitive landscape but does not directly impact its operations.
Aug 27, 2026 · 6 articles
20
International
United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.
Revolution Medicines: Revolution Medicines is the maker of daraxonrasib, an experimental pill showing promise for advanced pancreatic cancer, and plans to seek United States — Food and Drug Administration approval.
May 18, 2026 · 316 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Revolution Medicines interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.